The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Zolsketil Pegylated Liposomal

Accord Healthcare S.L.U.EU/1/22/1629/001-0004

Main Information

Trade NameZolsketil Pegylated Liposomal
Active SubstancesDoxorubicin Hydrochloride, Liposomal
Dosage FormConcentrate for dispersion for infusion
Licence HolderAccord Healthcare S.L.U.
Licence NumberEU/1/22/1629/001-0004

Group Information

ATC CodeL01DB01 doxorubicin


License statusAuthorised
Licence Issued31/05/2022
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characterististics, section 4.2)
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back